Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.

Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.

Item
http://www.wikidata.org/entity/Q34733877
A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiencyWeight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patientsProspective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.New options with dabigatran etexilate in anticoagulant therapyLaser-engineered dissolving microneedles for active transdermal delivery of nadroparin calciumDosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital.Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.Drug insight: an overview of current anticoagulation therapy after heart valve replacement.First trimester stroke prophylaxis in pregnant women with a history of stroke.The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin.Comparative Effectiveness of Enoxaparin versus Dalteparin for Thromboprophylaxis after Traumatic Injury.Treatment of deep venous thrombosis with low molecular weight heparins.Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals.Successful thrombolysis following enoxaparin therapy in two pediatric patients with congenital heart disease presenting with intracardiac and cerebral thrombosis.Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?
P2860

Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.

Item
http://www.wikidata.org/entity/Q34733877
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@ast
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@en
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@nl
type
label
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@ast
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@en
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@nl
prefLabel
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@ast
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@en
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@nl
P1433
P1476
P2093
P304
P31
P356
P478
P577
P698
P356
P1433
P1476
Low-molecular-weight heparins: ...... tics and metabolism in humans.
@en
P2093
P304
P31
P356
P478
P577
P698